CA-AMAZENTIS
27.7.2020 15:07:04 CEST | Business Wire | Press release
Pioneering life sciences company, Amazentis , today announces new clinical findings and the commercial launch of Timeline Cellular Nutrition in the United States. After a decade of research by leading scientists and medical doctors, Timeline Nutrition is the first brand to offer Mitopure™, a highly pure form of Urolithin A proven to help counter age-associated cellular decline and improve muscular strength.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200727005447/en/
- A randomized, double-blind, placebo-controlled clinical trial (NCT03464500 ) in healthy middle-aged participants (40 to 65 years old) showed that 4 months of daily consumption of 500mg Mitopure™ (highly pure Urolithin A) led to a significant improvement in leg muscle strength.
- A separate randomized clinical trial (NCT04160312 ) conducted in healthy adults (18-80 years old) in the USA compared Urolithin A levels following consumption of Mitopure™ and pomegranate juice. It showed that 500mg of Mitopure™ delivers greater than 6X more Urolithin A compared to 8oz (240ml) of 100% pomegranate juice.
- Amazentis is launching the first product containing clinically proven Mitopure™ exclusively direct-to-consumer through the Timeline Nutrition website.
Many people begin to experience a loss in muscle strength starting in their 40s due to age-associated declines in cellular bioenergetics and mitochondrial function. Timeline is formulated with Mitopure™, a proprietary ingredient and highly pure form of Urolithin A. This bioactive is produced by the gut microbiome in only a limited portion of the population. Mitopure™ is the only compound shown to increase muscle function by activating the selective recycling of damaged mitochondria (the powerhouse of the cell) via an essential anti-aging process known as mitophagy.
“For the first time we have now shown that consuming Mitopure™ on a regular basis for 4 months triggers meaningful physiological changes in the body and significantly improves leg muscle strength” says Amazentis Chairman & Co-Founder, Patrick Aebischer, MD “this is a breakthrough in the translation of science-backed nutrition targeting muscle and healthy aging.”
Timeline is particularly effective because precisely calibrated doses of Mitopure™ deliver Urolithin A directly and activate mitophagy within the body—regardless of your diet or microbiome. This new clinical data showed that only 12% of participants had detectable levels of Urolithin A entering the study. Overall, participants showed a greater than 6-fold improvement in Urolithin A levels over 24 hours after consuming 500mg of Mitopure™ when compared to 8oz (240mL) of 100% pomegranate juice.
“At Amazentis, we’re dedicated to developing the next generation of nutrition products targeting cellular health and mitochondrial function. Now, more than ever, consumers appreciate the importance of staying healthy and maintaining muscle function. Timeline Nutrition brings together cutting-edge science with a great tasting product,” says Amazentis CEO and Co-Founder, Chris Rinsch, PhD.
Timeline’s first product comes in the form of a delicious Berry & Pomegranate flavored powder that can be mixed in with your daily smoothie, yogurt, and other breakfast favorites. Timeline is exclusively available for purchase online for consumers in the United States starting at $3.33 per day for a four-month supply. Visit www.timelinenutrition.com for more information.
* 500mg of Mitopure™ have been shown to (1) induce gene expression related to mitochondrial function and metabolism and (2) increase the strength of the hamstring leg muscle in measures of knee extension and flexion in overweight 40 to 65 year olds. Data from two randomized double-blind placebo-controlled human clinical trials.
About Timeline
Timeline Nutrition is the first brand to offer Mitopure™, a highly pure form of Urolithin A. This novel nutrition brand was developed by Amazentis on the belief that uncompromising research can unlock a new class of nutrition that is backed by cutting edge science. As scientists, we know that physical decline from aging can’t be stopped. However, through its groundbreaking research, Timeline is committed to developing products designed to help reduce the impact of time on health. For more information, please visit www.timelinenutrition.com
.
About Mitopure™
Mitopure™ is a highly pure form of Urolithin A; a bioactive dietary metabolite that is produced by gut bacteria after eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone. Mitopure™ has been shown to improve mitochondrial function by stimulating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell, making way for healthy mitochondria to grow. Mitopure™ has been favorably reviewed by the U.S. Food and Drug Administration (FDA) and deemed safe following a GRAS (generally recognized as safe) filing. Mitopure™ has been extensively evaluated pre-clinically and clinically to support its use in humans for nutritional supplementation. For more information, please visit www.mitopure.com
.
About Amazentis
Amazentis is an innovative life sciences company employing today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. Amazentis has previously published its research on Mitopure™ Urolithin A in top peer reviewed scientific journals such as Nature Medicine
(doi:10.1038/nm.4132) and Nature Metabolism
(doi: 10.1038/s42255-019-0073-4). The company has a global strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™ linked to mitochondrial and cellular decline. For more information on Amazentis, please visit www.amazentis.com
.
Related Links
https://www.timelinenutrition.com
https://www.mitopure.com
https://www.amazentis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005447/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Garvan Institute of Medical Research Joins Parse Biosciences’ Certified Service Provider Network15.7.2026 22:00:00 CEST | Press release
Researchers across Asia-Pacific gain a new option for high-quality single cell sequencing through Garvan's Evercode WT services Parse Biosciences, a QIAGEN company, and the leader in scalable and accessible single cell sequencing, today announced that the Genomics Platform Core Facility within the Garvan Institute of Medical Research has joined its Certified Service Provider (CSP) Program. The partnership broadens access to high-quality, scalable single cell sequencing across Australia, the wider Asia-Pacific region, and beyond. Garvan is one of Australia's preeminent medical research institutions, with the Genomics Platform having deep experience in cell sorting, capture, and sequencing. As a Certified Service Provider, Garvan will offer Parse's Evercode WT kits to researchers across the region. "We see a growing number of requests for Parse projects and find the technology easy to implement and run, generating great data," said Chris O'Keeffe, Cellular Genomics Lead at the Garvan Ins
Grafana Labs Named a Leader in 2026 Gartner® Magic Quadrant™ for Observability Platforms and Positioned Furthest in Completeness of Vision15.7.2026 20:21:00 CEST | Press release
Named a Leader for the third consecutive year and placed furthest in vision for the second year in a row, the company has had a landmark year of innovation as observability becomes essential infrastructure for teams building and running AI at scale. Grafana Labs, the company behind the open observability cloud, today announced it has been named a Leader in the Gartner® Magic Quadrant™ for Observability Platforms for the third consecutive year, and positioned furthest on the Completeness of Vision axis for the second year running. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715814984/en/ 2026 Gartner® Magic Quadrant™ for Observability Platforms We believe this placement reflects where the market is headed: toward open, composable observability that helps teams in the AI era understand systems that are increasingly complex and agentic, and rapidly scaling thanks to AI-assisted engineering. A Platform Built for the AI Era
Spectro Cloud Raises $100 Million Series D to Help Customers Move AI Infrastructure Into Production Across Enterprise, Public Sector, Neocloud and Sovereign Cloud Environments15.7.2026 18:20:00 CEST | Press release
Growth Equity at Goldman Sachs Alternatives leads oversubscribed round with strategic participation from AMD Ventures, Ericsson, LG Technology Ventures, and Maximus as organizations look to turn AI silicon into business outcomes Spectro Cloud, a leading provider of AI infrastructure management software, today announced it has raised more than $100 million in an oversubscribed Series D funding round led by Growth Equity at Goldman Sachs Alternatives, with strategic participation from AMD Ventures, Ericsson, LG Technology Ventures, and Maximus. The new funding brings Spectro Cloud’s total capital raised to $260 million and will accelerate the company’s mission to help enterprises, public sector organizations, neoclouds and sovereign clouds build and operate production AI infrastructure with greater control over cost, security and governance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715551858/en/ Spectro Cloud raises $
K-Beauty Goes Global: Sales Surge 53% as Korean Innovation Reshapes Beauty Growth15.7.2026 16:00:00 CEST | Press release
New NIQ data shows K-Beauty value sales rose 53% year-over-year and 131% over two years, underscoring how regional beauty trends, social commerce and ingredient-led innovation are reshaping global beauty growth. NIQ (NYSE: NIQ), a global leader in consumer intelligence, today released new findings showing K-Beauty has become a rapidly growing global beauty segment, with value sales up 53% year-over-year and 131% over the past two years. The data points to a broader shift in beauty growth, as regional innovation, social commerce and digitally driven consumer demand increasingly shape what scales globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715867578/en/ K-Beauty accelerates across global markets In its latest report, K-Beauty Goes Global, NIQ shows how Korean beauty is reshaping consumer expectations, accelerating innovation cycles and redefining competitive dynamics across the global beauty market. What began
Viz.ai to Support the MINUTE Trial, a Landmark Multicenter Study Evaluating the SCUBA Technique for the Treatment of Intracerebral Hemorrhage15.7.2026 15:00:00 CEST | Press release
Viz Neuro™ Suite, including Viz ICH™ and Viz ICH Plus™, to facilitate rapid detection and care coordination for patients with basal ganglia hemorrhage across trial sites nationwide. Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced its support for the Minimally Invasive Neurosurgery Trial for Ultra-early Treatment (MINUTE) Trial, a prospective, multicenter, randomized study evaluating whether the SCUBA technique, an endoscopic, catheter-based approach for ultra-early evacuation of basal ganglia intracerebral hemorrhage (BGH), is a promising alternative to standard medical management to potentially improve functional patient outcomes. The study aims to initiate both randomization and surgical intervention within 120 minutes of key clinical time points, reflecting the urgent nature of intracerebral hemorrhage care. Participating sites will have the ability to leverage the Viz Neuro Suite platform, including Viz ICH and Viz ICH Plus, to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom